Company: HURA
Filing Date: 2025-08-12
Form Type: S-1
Source: 0001193125-25-179009
Chunk: 270

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-08-12
Form: S-1
Chunk 270
---
HURA surviving the Merger as a wholly owned subsidiary of the Company. Following the completion of the Merger, the Company changed its corporate name to “TuHURA Biosciences, Inc.” F-3 6

References to the Company refer to the Company and its wholly-owned subsidiaries. Going concern and management plans These condensed consolidated interim financial statements have been prepared on a going concern basis which assumes that the Company will continue its operations for the foreseeable future and contemplates the realization of assets and the settlement of liabilities in the normal course of business. For the three months ended September 30, 2024, the Company reported a loss of $ 2,161and a negative cash flow from operations of $ 1,889. The Company had an accumulated deficit of $ 162,052and had cash and cash equivalents of $ 3,020as of September 30, 2024. The Company is in the clinical stage and has not generated any revenues to date. The Company does not have the prospect of achieving revenues until such time that its product candidate is commercialized, or partnered, which may not ever occur. On August 2, 2022, the Company entered into a stock purchase agreement under which the Company has issued 19shares of common stock for $ 2,008in net proceeds as of September 30, 2024. In addition, on June 28, 2023, the Company announced that it had been awarded approximately $ 2,000in grant funding to be received over a two-yearperiod for its REM-001project.During the year ended June 30, 2024, the Company issued an additional 1,519shares of common stock for net proceeds of $ 10,471from its at-the-market(“ATM”) facility, and announced that it is suspending the development of VAL-083.Even with the proceeds from the grant funding, the stock purchase financing, and the ATM sales, the Company will require additional funding to maintain its clinical trials, research and development projects, and for general operations. These circumstances indicate substantial doubt exists about the Company’s ability to continue as a going concern within one yearfrom the date of filing of these condensed consolidated interim financial statements. On October 18, 2024, the Company completed the Merger with TuHURA, on and subject to the terms of the Merger Agreement (Note 11). Consequently, management is pursuing various financing alternatives to fund the Company’s operations so it can continue as a going